Microscopic polyangiitis historical perspective

Jump to navigation Jump to search

Microscopic polyangiitis Microchapters


Patient Information


Historical Perspective




Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Microscopic polyangiitis historical perspective

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis historical perspective

CDC on Microscopic polyangiitis historical perspective

Microscopic polyangiitis historical perspective in the news

Blogs on Microscopic polyangiitis historical perspective

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]


The early case reports of microscopic polyangiitis provide a historical context and foundation for better understanding of the current concepts of these diseases microscopic polyangiitis. Microscopic polyangiitis was first introduced by Dr. Friedrich Wohlwill, a German neuropathologist, who described two patients with transmural periarteritis with glomerulonephritis in 1923. Historically, most forms of vasculitis like microscopic polyangiitis described subsequently classified on the basis of features similar to or distinct from polyarteritis.

Historical Perspective


Landmark Events in the Development of Treatment Strategies

  • Rituximab plays an important role in the newly developed strategies in treating microscopic polyangiitis.[5]


  1. Wohlwill, F. (1923). "Über die nur mikroskopisch erkennbare Form der Periarteriitis nodosa". Virchows Arch. path Anat. 246 (1): 377–411. doi:doi:10.1007/BF01947911 Check |doi= value (help).
  2. Matteson EL (2002). "Historical perspective of vasculitis: polyarteritis nodosa and microscopic polyangiitis". Curr Rheumatol Rep. 4 (1): 67–74. PMID 11798985.
  3. Langford CA (May 2011). "Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis". Clin. Exp. Immunol. 164 Suppl 1: 31–4. doi:10.1111/j.1365-2249.2011.04364.x. PMC 3095863. PMID 21447129.
  4. Chung SA, Seo P (August 2010). "Microscopic polyangiitis". Rheum. Dis. Clin. North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
  5. Jayne D (January 2008). "Challenges in the management of microscopic polyangiitis: past, present and future". Curr Opin Rheumatol. 20 (1): 3–9. doi:10.1097/BOR.0b013e3282f370d1. PMID 18281850.

Template:WH Template:WS